Is treatment with octreotide effective in patients with head-and-neck paraganglioma? - octreotide in head and neck paraganglioma

Academisch Medisch Centrum0 个研究点目标入组 4 人开始时间: 待定最近更新: 2024年6月18日

适应症

试验速览

Trial ended prematurely

•-presence of one or more head-and-neck paraganglioma that grow fast (>/ 20%/year) and/or are complicated by recent cranial nerve palsy (<1 year ago)and/or production of catecholamines
•-age 18-75 years
•-positieve octreotidescan
•-informed consent

•-necessity for surgical resection of the head-and-neck paraganglioma
•-presence of additional paraganglioma in the thorax or abdomen
•-presence of metastases of the head-and-neck paraganglioma
•-cholelithiasis
•-diabetes mellitus
•-severe renal insufficiency (creatinine > 150 micromol/L), or liver failure(ALAt and/or ASAT increased >3x)
•-recent participation in other research projects (< 3 month's ago), or participation in >2 projects the past year
•-(wish for) pregnancy
•-presence of an adrenal tumor, suspect for phaeochromocytoma. These patients will be operated (adrenalectomy) first. In all other patients who participate, an MIBG scan and an MRI svan will be performed in case of overproduction of catecholamines

发起方